Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508180 | 1.00 | LPL (0.50) | LPLLIPGESR2F11CA1 | |
| SCHEMBL15774946 | 0.84 | LIPG (0.49) | LPLLIPGESR2F11CA1 | |
| SCHEMBL252566 | 0.82 | LPL (0.56) | LPLLIPGESR2F11CA1 | |
| SCHEMBL19996345 | 0.82 | LIPG (0.53) | LPLLIPGESR2F11CA1 | |
| SCHEMBL17680507 | 0.81 | ESR2 (0.36) | LPLLIPGESR2F11F2 | |
| SCHEMBL24774874 | 0.80 | LIPG (0.52) | LPLLIPGESR2F11CA1 | |
| SCHEMBL14694622 | 0.80 | LIPG (0.52) | LPLLIPGESR2F11CA1 | |
| SCHEMBL24775237 | 0.80 | LIPG (0.52) | LPLLIPGESR2F11CA1 | |
| SCHEMBL25056784 | 0.79 | LPL (0.53) | LPLLIPGESR2F11CA1 | |
| SCHEMBL25648947 | 0.79 | LPL (0.50) | LPLLIPGESR2F11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225196-B1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK CANADA INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8642799-B2 | Cysteine protease inhibitors for the treatment of parasitic diseases | MERCK CANADA INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100048717-A1 | CATHEPSIN B INHIBITORS | MERCK FROSST CANADA LTD, Merk & Co., Inc. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR52, GPR35 | LPL 401/4885LIPG 159/4885ESR2 139/4885 |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | CTSL, SERPINB1, CTSZ | LPL 1774/4885LIPG 1748/4885ESR2 4601/4885 |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | CTSL, SERPINB1, CTSZ | LPL 1028/4885LIPG 1110/4885ESR2 4517/4885 |
| US-20100048717-A1 | CATHEPSIN B INHIBITORS | CTSB, CTSF, CTSS | LPL 1533/4885LIPG 963/4885ESR2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.